BioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX) have been given an average rating of “Moderate Buy” by the fourteen brokerages that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $135.54.

A number of research firms have recently commented on BNTX. HC Wainwright increased their target price on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. UBS Group lifted their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Deutsche Bank Aktiengesellschaft raised their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and boosted their target price for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the business. Capital World Investors lifted its stake in BioNTech by 0.5% during the first quarter. Capital World Investors now owns 943,116 shares of the company’s stock worth $87,002,000 after purchasing an additional 4,369 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of BioNTech by 4.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after buying an additional 24,426 shares in the last quarter. Candriam S.C.A. increased its holdings in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after acquiring an additional 53,800 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of BioNTech by 283.5% in the second quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after buying an additional 341,311 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Stock Down 1.4 %

BNTX opened at $111.48 on Friday. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The stock has a market capitalization of $26.51 billion, a price-to-earnings ratio of -49.33 and a beta of 0.24. The firm has a 50 day moving average price of $109.72 and a 200-day moving average price of $95.77.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. BioNTech’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.86) EPS. Equities research analysts forecast that BioNTech will post -2.93 earnings per share for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.